Viewing StudyNCT02784158

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 8:37 AM
Last Modification Date: 2024-10-26 @ 12:03 PM
Study NCT ID: NCT02784158
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2018-02-06
First Post: 2016-05-24
Brief Title: An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Sponsor: Ariad Pharmaceuticals
Organization: Takeda
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Non-small Cell Lung Cancer
Lung Cancer
Advanced Malignancies
Carcinoma
Keywords:
Name View
Squamous cell carcinoma View
Non-small cell lung cancer View
Non-small cell lung carcinoma View
Epithelial lung cancer View
Large cell carcinoma View
Adenocarcinoma View
Anaplastic lymphoma kinase ALK View
Carcinoma View
Advanced Cancers View
Brigatinib View
AP26113 View